Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment

Background: Biomarkers are essential for identification of individuals at high risk of mild cognitive impairment (MCI) for potential prevention of dementia. We investigated DNA methylation in the <i>APOE</i> gene and apolipoprotein E (ApoE) plasma levels as MCI biomarkers in Colombian su...

Full description

Bibliographic Details
Main Authors: Oscar Mancera-Páez, Kelly Estrada-Orozco, María Fernanda Mahecha, Francy Cruz, Kely Bonilla-Vargas, Nicolás Sandoval, Esneyder Guerrero, David Salcedo-Tacuma, Jesús D. Melgarejo, Edwin Vega, Jenny Ortega-Rojas, Gustavo C. Román, Rodrigo Pardo-Turriago, Humberto Arboleda
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/20/6/1394
id doaj-387084542dc448d4a388ec41197af588
record_format Article
spelling doaj-387084542dc448d4a388ec41197af5882020-11-24T20:54:36ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-03-01206139410.3390/ijms20061394ijms20061394Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive ImpairmentOscar Mancera-Páez0Kelly Estrada-Orozco1María Fernanda Mahecha2Francy Cruz3Kely Bonilla-Vargas4Nicolás Sandoval5Esneyder Guerrero6David Salcedo-Tacuma7Jesús D. Melgarejo8Edwin Vega9Jenny Ortega-Rojas10Gustavo C. Román11Rodrigo Pardo-Turriago12Humberto Arboleda13Department of Neurology, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaNeurosciences Research Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaGenetic Institute, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaNeurosciences Research Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaNeurosciences Research Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaGenetic Institute, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaGenetic Institute, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaGenetic Institute, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaGenetic Institute, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaNeurosciences Research Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaGenetic Institute, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaDepartment of Neurology, Methodist Neurological Institute and the Institute for Academic Medicine Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX 77030, USADepartment of Neurology, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaNeurosciences Research Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaBackground: Biomarkers are essential for identification of individuals at high risk of mild cognitive impairment (MCI) for potential prevention of dementia. We investigated DNA methylation in the <i>APOE</i> gene and apolipoprotein E (ApoE) plasma levels as MCI biomarkers in Colombian subjects with MCI and controls. Methods: In total, 100 participants were included (71% women; average age, 70 years; range, 43&#8211;91 years). MCI was diagnosed by neuropsychological testing, medical and social history, activities of daily living, cognitive symptoms and neuroimaging. Using multivariate logistic regression models adjusted by age and gender, we examined the risk association of MCI with plasma ApoE and <i>APOE</i> methylation. Results: MCI was diagnosed in 41 subjects (average age, 66.5 &#177; 9.6 years) and compared with 59 controls. Elevated plasma ApoE and <i>APOE</i> methylation of CpGs 165, 190, and 198 were risk factors for MCI (<i>p</i> &lt; 0.05). Higher CpG-227 methylation correlated with lower risk for MCI (<i>p</i> = 0.002). Only CpG-227 was significantly correlated with plasma ApoE levels (correlation coefficient = &#8722;0.665; <i>p</i> = 0.008). Conclusion: Differential <i>APOE</i> methylation and increased plasma ApoE levels were correlated with MCI. These epigenetic patterns require confirmation in larger samples but could potentially be used as biomarkers to identify early stages of MCI.https://www.mdpi.com/1422-0067/20/6/1394<i>APOE</i> geneapolipoprotein EDNA methylationmild cognitive impairmentHispanics
collection DOAJ
language English
format Article
sources DOAJ
author Oscar Mancera-Páez
Kelly Estrada-Orozco
María Fernanda Mahecha
Francy Cruz
Kely Bonilla-Vargas
Nicolás Sandoval
Esneyder Guerrero
David Salcedo-Tacuma
Jesús D. Melgarejo
Edwin Vega
Jenny Ortega-Rojas
Gustavo C. Román
Rodrigo Pardo-Turriago
Humberto Arboleda
spellingShingle Oscar Mancera-Páez
Kelly Estrada-Orozco
María Fernanda Mahecha
Francy Cruz
Kely Bonilla-Vargas
Nicolás Sandoval
Esneyder Guerrero
David Salcedo-Tacuma
Jesús D. Melgarejo
Edwin Vega
Jenny Ortega-Rojas
Gustavo C. Román
Rodrigo Pardo-Turriago
Humberto Arboleda
Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment
International Journal of Molecular Sciences
<i>APOE</i> gene
apolipoprotein E
DNA methylation
mild cognitive impairment
Hispanics
author_facet Oscar Mancera-Páez
Kelly Estrada-Orozco
María Fernanda Mahecha
Francy Cruz
Kely Bonilla-Vargas
Nicolás Sandoval
Esneyder Guerrero
David Salcedo-Tacuma
Jesús D. Melgarejo
Edwin Vega
Jenny Ortega-Rojas
Gustavo C. Román
Rodrigo Pardo-Turriago
Humberto Arboleda
author_sort Oscar Mancera-Páez
title Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment
title_short Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment
title_full Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment
title_fullStr Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment
title_full_unstemmed Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment
title_sort differential methylation in <i>apoe</i> (chr19; exon four; from 44,909,188 to 44,909,373/hg38) and increased apolipoprotein e plasma levels in subjects with mild cognitive impairment
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2019-03-01
description Background: Biomarkers are essential for identification of individuals at high risk of mild cognitive impairment (MCI) for potential prevention of dementia. We investigated DNA methylation in the <i>APOE</i> gene and apolipoprotein E (ApoE) plasma levels as MCI biomarkers in Colombian subjects with MCI and controls. Methods: In total, 100 participants were included (71% women; average age, 70 years; range, 43&#8211;91 years). MCI was diagnosed by neuropsychological testing, medical and social history, activities of daily living, cognitive symptoms and neuroimaging. Using multivariate logistic regression models adjusted by age and gender, we examined the risk association of MCI with plasma ApoE and <i>APOE</i> methylation. Results: MCI was diagnosed in 41 subjects (average age, 66.5 &#177; 9.6 years) and compared with 59 controls. Elevated plasma ApoE and <i>APOE</i> methylation of CpGs 165, 190, and 198 were risk factors for MCI (<i>p</i> &lt; 0.05). Higher CpG-227 methylation correlated with lower risk for MCI (<i>p</i> = 0.002). Only CpG-227 was significantly correlated with plasma ApoE levels (correlation coefficient = &#8722;0.665; <i>p</i> = 0.008). Conclusion: Differential <i>APOE</i> methylation and increased plasma ApoE levels were correlated with MCI. These epigenetic patterns require confirmation in larger samples but could potentially be used as biomarkers to identify early stages of MCI.
topic <i>APOE</i> gene
apolipoprotein E
DNA methylation
mild cognitive impairment
Hispanics
url https://www.mdpi.com/1422-0067/20/6/1394
work_keys_str_mv AT oscarmancerapaez differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT kellyestradaorozco differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT mariafernandamahecha differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT francycruz differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT kelybonillavargas differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT nicolassandoval differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT esneyderguerrero differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT davidsalcedotacuma differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT jesusdmelgarejo differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT edwinvega differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT jennyortegarojas differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT gustavocroman differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT rodrigopardoturriago differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
AT humbertoarboleda differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment
_version_ 1716793928407056384